Both the Centers for Disease Control and the World Health Organization have advised that athletes regularly use condoms if they must have sex at all, during the Rio Olympics in Brazil.
The Australian Olympic team has announced that it will be given a new way to fight off the Zika virus: a condom said to be "Zika-proof," even though the manufacturer's website states that it has not applied for or received regulatory approval for its claim.
The summer Olympics are scheduled to be held August 5-21 in Rio de Janeiro. Brazil has been the epicenter of the latest outbreak of the Zika virus, which is linked to an alarming rise in birth defects and other neurological and nervous system disorders.
Australian pharmaceutical company Starpharma Holdings Ltd. and marketing company Ansell Limited announced that the Australian team will be given Ansell's Dual Protect condoms lubricated with Starpharma's VivaGel lubricant, an antiviral agent the company claims can protect against bad vaginal bacteria, some STDs and, now, Zika.
The virus is primarily transmitted by infected mosquitoes but is also sexually transmitted.
In an early May news release (PDF), the company said VivaGel had shown "potent antiviral activity against the Zika virus in laboratory studies." The studies reportedly showed "near complete antiviral protection" at concentrations "significantly below that used in the VivaGel condom."
"Given sexual transmission of Zika virus is of increasing importance," Starpharma's chief executive officer, Dr. Jackie Fairley, said in an online statement, "Starpharma is delighted to play a role in supporting Australian athletes as they compete on the world-stage at the Olympic Games in Rio."
In the same statement, Australian Olympic Team Chief de Mission Kitty Chiller said, "The health and wellbeing of the Team comes first. Our association with Starpharma will provide extra protection for everyone on the Team, and is a common sense approach to a very serious problem we are facing in Rio."
VivaGel, or astodrimer sodium, is being studied by the FDA as a method to prevent sexual transmission of HIV and herpes simplex 2. Starpharma says it is also effective against human papillomavirus.
VivaGel, created by nanotechnology, is applied to the vagina or rectum as a pre-exposure prophylaxis (PrEP) product. In the case of HIV, it works by keeping the virus from attaching to susceptible healthy cells.
Laboratory results showed potent antiviral activity against HIV 1 and HIV 2 for at least three hours post-dose, but two 2011 randomized trials found that twice daily use for two weeks caused irritation and low-grade inflammation, which researchers suggest might counter some of the anti-viral effects.